drugset / Trial / NCT03406715
Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)
Phase 2
Terminated
14 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb · collabMultiVir, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects (good and bad) immunotherapy treatment using the p53 vaccine (Ad.p53-DC) in combination with Nivolumab and Ipilimumab has on small cell lung cancer. Immunotherapy is a cancer therapy that uses the body's immune system to fight cancer cells. This study can be divided into three different phases: initial Induction Immunotherapy, Maintenance Immunotherapy and Retreatment.
Timeline
- Start
- 2018-03-15
- Primary completion
- 2022-03-23
- Completion
- 2022-05-16
Outcome
Outcome not reported
Stopped: “Sponsor closed study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dendritic Cell based p53 Vaccine | Vaccine | — | — |
| Subject | Ipilimumab | Monoclonal antibody | — | — |
| Subject | Nivolumab | Monoclonal antibody | — | — |